| Literature DB >> 35503503 |
Weidong Zhang1, Sunhee Ro2, Qi Jiang3, Xiaoyun Li4, Rong Liu5, Chengxing 'Cindy' Lu6, Olga Marchenko7, Jing Zhao8, Zhenzhen Xu9.
Abstract
In biomarker enrichment study designs that start with an all-comer population, simultaneous evaluation of the entire and the marker-selected populations can be more desirable than pre-specifying the testing order, when the degree of marker predictiveness is uncertain. While there has been substantial research on this approach, our goal is to provide a complete overview and guidance in all aspects of this approach, including the interim analysis potentially using different endpoints, combination tests with associated multiplicity control, and the final treatment effect estimation. Regulatory/operational aspects and actual cases demonstrating the potential advantage of this approach are also described.Entities:
Keywords: Adaptive design; Biomarker; Oncology confirmatory trial; Population enrichment; Two-stage design
Mesh:
Substances:
Year: 2022 PMID: 35503503 DOI: 10.1007/s43441-022-00407-y
Source DB: PubMed Journal: Ther Innov Regul Sci ISSN: 2168-4790 Impact factor: 1.778